

**ASX Announcement**  
**11 July 2025**

**Tissue Repair appoints leading Australia and New Zealand Aesthetics Distributor for TR Pro+® and launches international expansion with appointment of leading Asian aesthetics distributor in Thailand. These appointments coincide with the move to establish commercial scale production to support global expansion of the TR Pro product line.**

**Sydney, Australia** – *Tissue Repair Limited* (ASX: TRP), a clinical-stage biotechnology company focused on advanced wound healing and skin regeneration, has signed a multi-year distribution agreement with *Advanced Cosmeceuticals Pty Ltd*, Australia's leading aesthetics and cosmeceutical skincare distributor, to launch its flagship product *TR Pro+®* across Australia and New Zealand.

With access to over 2,500 clinics and a network that spans specialist skin clinics, dermatologists, plastic surgeons, pharmacies, and major online retailers, Advanced Cosmeceuticals is uniquely positioned to deliver national reach across aesthetic and medical aesthetic channels. Advanced Cosmeceuticals, owned by Gresham, has a close ownership relationship with Wesfarmers which owns Priceline and Silk Clinics.

Under the agreement, Advanced Cosmeceuticals will lead the commercial rollout of TR Pro+® across three key channels:

1. **Clinics:** Targeting distribution to more than 2,500 dermatology, aesthetic, and plastic surgery clinics and increasing in-clinic usage through integration of TR Pro+® in post-procedure treatment protocols. This represents a material expansion from the 200 clinic footprint from the Australian pilot the Company has been running.
2. **Pharmacies:** Leveraging TR Pro+®'s TGA-listed medicine status to enter leading pharmacy chains including Chemist Warehouse, Priceline, Terry White and Blooms The Chemist.
3. **Online Retail:** Growing presence through e-commerce partners such as Adore Beauty and Advanced Cosmeceuticals direct to consumer (D2C) platform.

To support this strategy, Tissue Repair will release TR Pro+® in four formats—10g, 30g, 50g, and a 200g professional-use size—targeting both clinical and retail markets.

This partnership marks Tissue Repair's transition from a development-stage biotech company to a revenue-generating enterprise, validating global expansion potential of the product line and enabling rapid market access through one of the most experienced distributors in the region.

**Tony Charara**, CEO and Co-founder of Tissue Repair, said: *"This agreement with Australia's leading aesthetic distributor fast-tracks our commercialisation goals. It allows us to deliver TR Pro+® to clinicians and patients seeking faster skin recovery and superior post-procedure care, while laying the foundation for global expansion. We anticipate this partnership to drive meaningful growth as we embark on the next phase of our global distribution strategy for the product line."*

**Olivier Duvillard**, Non-Executive Director of Advanced Cosmeceuticals and former CEO of Ultraceuticles, former managing director at L'Oréal, and also holding prior senior executive roles at Elizabeth Arden, and Jurlique, added: *"TR Pro+® is backed by compelling clinical mechanism of action,*

*and histological evidence. It has the potential to become a frontline therapy for post-aesthetic recovery, delivering efficacy levels the market has long needed.”*

With ANZ distribution secured, Tissue Repair will refocus on its core strength, innovation. This includes advancing its regulatory strategy through the FDA 510(k) and CE Mark pathways and progressing the development of a new rejuvenating serum powered by its proprietary *Glucoprime*® healing technology. The serum is expected to launch via Advanced Cosmeceuticals’ platform in due course.

TR Pro+® is expected to formally launch at scale Australia-wide in February 2026, with an earlier soft launch currently under consideration.

### **International Expansion Begins with Thailand Agreement**

Tissue Repair has also signed its first international distribution agreement with *Amellie and Proud Co., Ltd* for exclusive distribution of TR Pro+® in Thailand.

A recognised leader in the Thai premium aesthetics and cosmeceutical market, Amellie and Proud will focus on introducing TR Pro+® to leading clinics and dermatology professionals, beginning with the 10g SKU. Additional formats will follow based on market demand.

This partnership opens one of Southeast Asia’s most dynamic aesthetics markets and signals the start of a broader global expansion strategy.

### **TR Pro+® Medical Line Remains Under Company Control**

Tissue Repair has retained global rights to its second TR Pro+® product line targeting medical and acute wound care. The product is already approved under its TGA-listed medicine classification for both medical and aesthetic indications.

Plans are underway for a dedicated launch targeting pharmacies, aged care, and healthcare professionals.

Simultaneously, the Company is pursuing international regulatory approvals expected within 9–12 months, including:

- **United States:** 510(k) pathway for aesthetic, acute, and chronic wounds
- **Europe and Asia:** Class I CE Mark
- **Australia:** TGA Listed Medicine already secured

These regulatory pathways enable the TR Pro+® product line to access very large international markets.

### **Strong Demand During Australian Pilot**

The appointment of these initial leading distributors follows the Company’s pilot program in Australia managed by TR Pro+®’s internal team which saw stronger-than-expected demand, resulting in temporary stock shortages during July. The situation is being actively managed and highlights the product’s market readiness.

Following the success of the pilot and the emergence of near-term regulatory pathways globally, Tissue Repair is now accelerating its commercial scale up strategy to support expected global demand from additional distribution partnerships.

**Commercial Manufacturing Scale-Up Underway**

To meet growing demand, Tissue Repair is moving to commercial-scale manufacturing, expanding our reactor vessels to afford the ability to supply at scale commensurate with expected global demand. A preferred manufacturing partner has been selected, with scaled production expected by late 2026.

The expansion will also generate valuable CMC data to support our future IND FDA drug application.

---

**For further information, please contact:****Darryl Reed**

darryl.reed@trtherapeutics.com

+61 419 557 663

*This announcement has been approved for release by the Board of Tissue Repair Limited.*

---

**About Tissue Repair**

Tissue Repair Limited (ASX: TRP) is a Phase 3 biotechnology company developing second-generation wound healing agents. The company is advancing its lead drug candidate *TR987*<sup>®</sup> for chronic wounds and commercialising *TR Pro+*<sup>®</sup>, a topical treatment designed to accelerate healing and improve skin quality following cosmetic or medical procedures. Its proprietary *Glucoprime*<sup>®</sup> API underpins a growing pipeline of therapeutic solutions.